Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Biotech Inc.

http://www.janssenbiotech.com

Latest From Janssen Biotech Inc.

Mainstays Give And Take As Major Japan Firms Report Results

While Daiichi Sankyo reveals ambitious plan with Enhertu, Chugai shows stable growth plans with COVID-19 drugs, Astellas reacted to concerns over Xtandi’s slow growth with enthusiastic investment plan for the next potential star.

Japan Commercial

COVID-19 Vaccines: With Narrowed Authorization For Janssen, US FDA Catches Up To CDC

Citing risk of thrombosis with thrombocytopenia syndrome, FDA restricts adenovirus-based vaccine to adults for whom other vaccines are not accessible or clinically appropriate, or who would not otherwise get a vaccine; action comes almost five months after CDC decided to preferentially favor the mRNA vaccines from Pfizer/BioNTech and Moderna.

Coronavirus COVID-19 Vaccines

Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Deal Watch Business Strategies

Janssen Seeking Medicare Add-On Payments For CAR-T Carvykti, But CMS May Be Skeptical

J&J will need to convince the Centers for Medicare and Medicaid Services that its treatment is not substantially similar to existing CAR-T’s in order to qualify for supplemental Medicare reimbursement.

Medicare Reimbursement
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
UsernamePublicRestriction

Register